| Distribution | Full List | Categories |
| by Country | by Vaccine |
| PEOPLE VACCINATED | LAST 7 DAYS | |||||
| countries over 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
| United Arab Emirates |
79.0% 7,813,548 |
70.6% 6,982,740 |
1.3% | 2.2% |
3.2% 315k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V | ||||||
| Uruguay |
73.8% 2,564,904 |
64.0% 2,223,205 |
0.9% | 2.7% |
3.6% 125k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Singapore |
73.6% 4,307,602 |
58.0% 3,391,799 |
1.3% | 6.3% |
7.6% 446k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Denmark |
72.6% 4,204,834 |
55.2% 3,194,779 |
2.1% | 4.2% |
6.3% 364k |
|
| Johnson&Johnson, Moderna, Pfizer/BioNTech | ||||||
| Chile |
72.3% 13,828,490 |
64.4% 12,320,188 |
0.4% | 1.4% |
1.7% 333k |
|
| CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Canada |
71.8% 27,111,943 |
59.4% 22,413,423 |
0.9% | 4.2% |
5.1% 1,940k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Qatar |
71.7% 2,065,408 |
60.4% 1,738,890 |
3.0% | 2.0% |
4.9% 142k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Netherlands |
69.2% 11,855,109 |
50.5% 8,657,328 |
0.5% | 3.9% |
4.4% 751k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| United Kingdom |
69.0% 46,851,145 |
56.5% 38,345,841 |
0.4% | 1.7% |
2.2% 1,463k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Belgium |
69.0% 7,993,557 |
57.2% 6,630,964 |
1.1% | 5.4% |
6.4% 743k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Portugal |
68.8% 7,010,170 |
55.8% 5,685,309 |
2.1% | 5.3% |
6.1% 623k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Spain |
68.1% 31,851,618 |
57.6% 26,933,847 |
2.9% | 3.3% |
5.8% 2,737k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Ireland |
67.0% 3,307,341 |
55.9% 2,758,980 |
3.3% | 3.5% |
6.3% 309k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Israel |
66.9% 5,787,665 |
62.1% 5,378,096 |
0.3% | 0.8% |
1.1% 95k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Finland |
66.7% 3,696,811 |
35.3% 1,956,843 |
1.1% | 3.8% |
4.9% 271k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Mongolia |
66.5% 2,178,913 |
60.5% 1,983,005 |
1.2% | 1.6% |
2.8% 93k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Norway |
65.8% 3,565,349 |
33.2% 1,800,693 |
3.3% | 1.3% |
4.6% 248k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Bahrain |
65.2% 1,109,612 |
62.1% 1,057,053 |
0.4% | 0.8% |
2.4% 40k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| France |
63.8% 41,673,008 |
48.8% 31,841,857 |
3.9% | 3.2% |
6.9% 4,524k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Italy |
63.7% 38,500,495 |
52.3% 31,595,863 |
1.8% | 3.8% |
5.5% 3,345k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Sweden |
63.3% 6,392,465 |
41.3% 4,172,893 |
1.9% | 2.3% |
4.2% 423k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Germany |
61.2% 51,241,053 |
51.6% 43,213,380 |
0.8% | 2.8% |
3.4% 2,867k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Austria |
58.8% 5,296,374 |
51.3% 4,621,776 |
0.6% | 2.8% |
3.3% 295k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| United States |
57.8% 191,498,983 |
49.8% 164,757,423 |
0.9% | 0.5% |
1.4% 4,638k |
|
| Johnson&Johnson, Moderna, Pfizer/BioNTech | ||||||
| Hungary |
56.6% 5,468,205 |
50.1% 4,842,148 |
0.6% | 3.6% |
3.3% 316k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Argentina |
55.5% 25,092,667 |
15.6% 7,056,120 |
3.0% | 2.3% |
5.4% 2,426k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Greece |
54.8% 5,706,360 |
49.6% 5,167,260 |
1.0% | 2.7% |
3.6% 376k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Saudi Arabia |
54.5% 18,979,146 |
24.0% 8,343,671 |
1.5% | 6.0% |
7.6% 2,634k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Czechia |
52.7% 5,647,184 |
45.3% 4,855,230 |
1.1% | 2.4% |
3.3% 359k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Lithuania |
52.0% 1,415,161 |
45.8% 1,246,226 |
2.3% | 1.4% |
3.6% 99k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Ecuador |
51.3% 9,047,885 |
13.4% 2,371,921 |
7.9% | 1.9% |
9.9% 1,742k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Dominican Republic |
51.1% 5,543,146 |
38.9% 4,215,901 |
0.8% | 2.0% |
3.7% 399k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Mauritius |
49.8% 634,013 |
41.1% 522,469 |
2.0% | 7.1% |
9.1% 116k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Brazil |
49.4% 105,057,816 |
19.5% 41,489,804 |
3.1% | 2.0% |
5.0% 10,643k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Turkey |
48.7% 41,062,834 |
32.6% 27,472,822 |
1.7% | 5.0% |
7.9% 6,687k |
|
| Pfizer/BioNTech, Sinovac | ||||||
| Poland |
48.4% 18,332,060 |
46.2% 17,470,071 |
0.7% | 1.4% |
1.8% 690k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Estonia |
48.2% 639,086 |
37.3% 494,758 |
1.5% | 1.0% |
2.5% 34k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Sri Lanka |
46.4% 9,944,683 |
10.1% 2,154,206 |
13.2% | 1.7% |
14.9% 3,191k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Costa Rica |
46.2% 2,352,430 |
16.5% 841,465 |
7.3% | 0.2% |
7.5% 381k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Slovenia |
44.3% 920,082 |
39.0% 810,211 |
1.1% | 1.0% |
2.1% 43k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Cambodia |
44.2% 7,385,013 |
29.0% 4,847,246 |
3.8% | 2.2% |
6.0% 1,009k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Malaysia |
44.0% 14,247,659 |
21.5% 6,952,814 |
7.2% | 4.3% |
11.6% 3,737k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Panama |
43.5% 1,878,898 |
16.1% 694,328 |
11.5% | 0.3% |
11.7% 507k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| El Salvador |
43.5% 2,821,728 |
22.9% 1,487,461 |
4.5% | 1.2% |
5.7% 372k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| China |
43.2% 622,000,000 |
15.5% 223,299,000 |
8.3% 119,259k |
|||
| CanSino, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac | ||||||
| Serbia |
41.7% 2,835,895 |
39.7% 2,700,275 |
0.3% | 0.4% |
0.7% 50k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Slovakia |
41.3% 2,257,621 |
35.9% 1,962,189 |
0.4% | 0.8% |
1.2% 65k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Latvia |
40.8% 768,947 |
36.3% 684,074 |
1.0% | 1.0% |
1.8% 34k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Croatia |
40.1% 1,646,466 |
34.9% 1,431,898 |
0.6% | 1.1% |
1.7% 71k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Japan |
39.8% 50,356,795 |
29.3% 37,024,867 |
2.0% | 3.2% |
5.2% 6,549k |
|
| Moderna, Pfizer/BioNTech | ||||||
| South Korea |
37.9% 19,444,120 |
13.9% 7,145,922 |
5.0% | 0.5% |
5.5% 2,813k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Morocco |
37.0% 13,672,764 |
27.4% 10,129,424 |
5.2% | 0.9% |
6.1% 2,256k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Mexico |
36.8% 47,463,637 |
20.0% 25,792,543 |
4.1% | 1.4% |
5.3% 6,797k |
|
| CanSino, Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Colombia |
35.0% 17,801,838 |
23.9% 12,179,103 |
3.3% | 2.0% |
4.6% 2,361k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Kuwait |
34.0% 1,452,148 |
21.6% 923,307 |
2.2% | 3.0% |
1.9% 81k |
|
| Pfizer/BioNTech | ||||||
| Cuba |
33.8% 3,833,448 |
23.1% 2,620,050 |
3.2% | 2.0% |
7.5% 846k |
|
| Abdala, Soberana02 | ||||||
| Taiwan |
33.1% 7,881,726 |
1.6% 388,487 |
6.1% | 0.6% |
6.7% 1,596k |
|
| Moderna, Oxford/AstraZeneca | ||||||
| Australia |
33.0% 8,424,188 |
15.3% 3,893,539 |
2.4% | 2.2% |
4.6% 1,177k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Oman |
30.4% 1,550,910 |
6.6% 336,511 |
1.4% | 0.6% |
2.0% 101k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Jordan |
29.5% 3,004,698 |
22.1% 2,260,376 |
2.1% | 2.0% |
4.1% 416k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Azerbaijan |
28.8% 2,923,477 |
20.9% 2,117,301 |
2.7% | 2.0% |
4.7% 477k |
|
| Oxford/AstraZeneca, Sinovac, Sputnik V | ||||||
| Kazakhstan |
28.8% 5,408,959 |
20.2% 3,799,879 |
1.5% | 3.0% |
4.5% 850k |
|
| QazVac, Sinopharm/HayatVax, Sputnik V | ||||||
| Trinidad and Tobago |
28.1% 392,650 |
13.9% 195,070 |
4.1% | 1.0% |
5.1% 71k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| WORLD |
27.5% 2,147,483,647 |
14.7% 1,143,446,607 |
0.2% | 0.8% | ||
| India |
26.7% 367,994,586 |
7.6% 104,229,053 |
1.9% | 0.8% |
2.7% 37,028k |
|
| Covaxin, Oxford/AstraZeneca, Sputnik V | ||||||
| Romania |
26.0% 4,993,968 |
25.3% 4,864,843 |
0.3% | 0.4% |
0.5% 96k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Paraguay |
25.8% 1,837,008 |
4.0% 286,989 |
6.1% | 0.6% |
6.7% 475k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Russia |
25.2% 36,759,116 |
17.5% 25,466,493 |
1.4% | 1.8% |
3.2% 4,732k |
|
| EpiVacCorona, Sputnik V | ||||||
| Bolivia |
24.7% 2,881,439 |
14.1% 1,644,738 |
0.8% | 3.3% |
4.1% 474k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| North Macedonia |
24.7% 514,021 |
18.8% 390,562 |
1.1% | 2.5% |
3.6% 76k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Peru |
24.2% 7,997,150 |
15.6% 5,155,135 |
1.0% | 2.0% |
3.1% 1,021k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Albania |
23.3% 670,215 |
18.4% 528,718 |
1.2% | 1.2% |
2.4% 69k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| New Zealand |
22.0% 1,059,685 |
14.5% 699,469 |
2.8% | 1.5% |
4.2% 205k |
|
| Pfizer/BioNTech | ||||||
| Timor |
21.0% 276,510 |
6.6% 86,759 |
1.6% | 1.8% |
3.4% 45k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Thailand |
17.6% 12,307,788 |
5.2% 3,652,990 |
2.1% | 0.3% |
2.4% 1,662k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Indonesia |
17.4% 47,478,168 |
7.6% 20,673,079 |
1.1% | 1.0% |
2.1% 5,775k |
|
| Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Lebanon |
16.3% 1,114,578 |
12.2% 834,680 |
0.5% | 1.5% |
2.1% 142k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Honduras |
16.1% 1,597,377 |
3.2% 315,170 |
1.9% | 1.4% |
3.4% 334k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V | ||||||
| Bulgaria |
14.8% 1,029,158 |
14.4% 1,001,143 |
0.1% | 0.8% |
0.9% 59k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Kosovo |
14.6% 282,603 |
7.6% 146,215 |
1.9% | 2.0% |
3.9% 75k |
|
| Oxford/AstraZeneca | ||||||
| Laos |
14.6% 1,062,365 |
11.4% 832,673 |
0.1% | 2.0% |
1.4% 103k |
|
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Tunisia |
14.4% 1,699,805 |
8.1% 963,633 |
0.9% | 1.2% |
2.1% 243k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Belarus |
14.1% 1,334,540 |
9.1% 860,453 |
1.0% | 1.1% |
2.1% 201k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Nepal |
13.9% 4,064,288 |
6.2% 1,813,471 |
2.3% | 1.4% |
3.8% 1,097k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Moldova |
13.6% 549,478 |
12.3% 495,051 |
0.8% | 1.4% |
2.2% 89k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Equatorial Guinea |
12.8% 178,913 |
8.7% 122,500 |
0.6% | 0.3% |
0.9% 13k |
|
| Sinopharm/Beijing | ||||||
| Bosnia and Herzegovina |
11.6% 381,381 |
7.0% 230,260 |
1.0% | 0.9% |
1.9% 62k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Palestine |
11.6% 591,569 |
8.1% 415,914 |
0.3% | 0.2% |
0.6% 28k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V | ||||||
| Uzbekistan |
11.0% 3,667,979 |
3.1% 1,023,425 |
1.2% | 0.0% |
1.9% 622k |
|
| Oxford/AstraZeneca, RBD-Dimer, Sputnik V | ||||||
| Philippines |
10.5% 11,524,212 |
7.2% 7,835,715 |
0.8% | 2.2% |
3.0% 3,275k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Zimbabwe |
10.5% 1,562,285 |
4.8% 713,131 |
1.8% | 0.4% |
2.2% 326k |
|
| Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Venezuela |
10.2% 2,900,000 |
3.9% 1,100,000 |
2.2% | 3.1% |
5.2% 1,492k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Guatemala |
10.2% 1,824,440 |
1.9% 335,634 |
2.4% | 0.2% |
2.6% 459k |
|
| Moderna, Oxford/AstraZeneca | ||||||
| South Africa |
10.0% 5,921,627 |
4.8% 2,835,930 |
1.5% | 1.1% |
2.0% 1,213k |
|
| Johnson&Johnson, Pfizer/BioNTech | ||||||
| Botswana |
9.7% 227,982 |
5.3% 124,425 |
1.2% | 0.3% |
1.5% 34k |
|
| Oxford/AstraZeneca | ||||||
| Iran |
9.2% 7,741,936 |
2.9% 2,426,738 |
2.2% | 0.2% |
2.4% 2,013k |
|
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Georgia |
8.6% 345,238 |
4.1% 161,542 |
2.0% | 0.6% |
2.6% 102k |
|
| Oxford/AstraZeneca | ||||||
| Ukraine |
8.2% 3,599,167 |
4.7% 2,033,616 |
1.1% | 0.7% |
1.9% 820k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac | ||||||
| Libya |
8.0% 546,745 |
0.7% |
0.7% 47k |
|||
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V | ||||||
| Algeria |
7.8% 3,421,279 |
1.6% 724,812 |
0.3% | 0.1% |
0.3% 146k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Kyrgyzstan |
7.1% 461,947 |
1.8% 117,311 |
1.0% | 0.1% |
1.1% 73k |
|
| Sinopharm/Beijing, Sputnik V | ||||||
| Namibia |
6.4% 162,596 |
1.9% 48,814 |
0.6% | 0.2% |
0.8% 20k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Jamaica |
6.0% 178,728 |
4.1% 122,174 |
0.0% | 0.1% |
0.2% 5k |
|
| Oxford/AstraZeneca | ||||||
| Vietnam |
5.9% 5,756,155 |
0.7% 659,064 |
1.6% | 0.3% |
1.9% 1,802k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Bangladesh |
5.3% 8,803,650 |
2.6% 4,338,165 |
1.7% | 0.0% |
1.7% 2,775k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Tajikistan |
4.8% 462,542 |
0.3% 29,524 |
0.3% | 0.1% |
0.4% 40k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Pakistan |
4.2% 9,308,890 |
2.9% 6,503,987 |
0.6% |
1.9% 4,132k |
||
| CanSino, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Armenia |
4.1% 120,285 |
1.7% 51,605 |
0.4% | 0.3% |
0.6% 19k |
|
| Oxford/AstraZeneca, Sinovac, Sputnik V | ||||||
| Guinea |
3.9% 516,973 |
2.2% 287,149 |
0.1% | 0.0% |
0.1% 15k |
|
| Sputnik V | ||||||
| Mauritania |
3.8% 178,483 |
0.3% 15,293 |
0.1% | 0.0% |
0.1% 3k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Nicaragua |
3.8% 252,766 |
2.5% 162,874 |
0.2% | 0.3% |
0.5% 31k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Senegal |
3.8% 640,013 |
1.6% 266,544 |
0.2% | 0.0% |
0.2% 36k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Togo |
3.7% 304,278 |
1.8% 149,930 |
0.1% | 0.2% |
0.2% 19k |
|
| Oxford/AstraZeneca | ||||||
| Cote d'Ivoire |
3.6% 959,349 |
0.2% |
0.2% 53k |
|||
| Oxford/AstraZeneca | ||||||
| Egypt |
3.6% 3,697,974 |
1.6% 1,639,532 |
0.0% | 0.1% |
0.1% 141k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||
| Myanmar |
3.4% 1,840,758 |
2.8% 1,527,284 |
0.1% 36k |
|||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Rwanda |
3.0% 394,067 |
2.0% 252,842 |
0.1% | 0.0% |
0.1% 14k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Angola |
2.9% 958,373 |
1.9% 634,164 |
0.1% |
0.1% 34k |
||
| Oxford/AstraZeneca | ||||||
| Ghana |
2.8% 865,422 |
1.3% 405,971 |
0.0% | 0.0% |
0.0% 6k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Uganda |
2.5% 1,143,763 |
0.0% 4,129 |
0.1% |
0.1% 29k |
||
| Oxford/AstraZeneca | ||||||
| Congo |
2.4% 132,671 |
1.2% 66,027 |
0.2% | 0.6% |
0.3% 17k |
|
| Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| Gabon |
2.4% 52,830 |
1.5% 34,351 |
0.2% | 0.2% |
0.4% 9k |
|
| Sinopharm/Beijing | ||||||
| Malawi |
2.2% 410,724 |
0.5% 93,471 |
0.0% | 0.1% |
0.1% 18k |
|
| Oxford/AstraZeneca | ||||||
| Afghanistan |
2.0% 763,020 |
0.6% 219,159 |
0.0% |
0.5% 183k |
||
| Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Kenya |
2.0% 1,055,341 |
1.2% 652,393 |
0.0% | 0.1% |
0.1% 59k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Ethiopia |
1.9% 2,217,097 |
0.0% |
0.0% 45k |
|||
| Oxford/AstraZeneca | ||||||
| Central African Republic |
1.8% 85,381 |
0.2% 8,409 |
0.0% | 0.1% |
0.1% 4k |
|
| Covaxin, Oxford/AstraZeneca | ||||||
| Iraq |
1.7% 699,325 |
1.0% 388,541 |
0.2% | 0.2% |
0.3% 132k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Lesotho |
1.7% 36,637 |
1.7% 36,311 |
0.3% |
0.3% 6k |
||
| Oxford/AstraZeneca | ||||||
| Liberia |
1.7% 86,288 |
0.2% 9,135 |
0.0% | 0.0% |
0.1% 3k |
|
| Oxford/AstraZeneca | ||||||
| Zambia |
1.5% 285,288 |
0.8% 153,597 |
0.1% | 0.3% |
0.5% 84k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Niger |
1.5% 363,018 |
0.2% 60,317 |
0.4% | 0.1% |
0.4% 107k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Sudan |
1.4% 627,833 |
0.4% 182,727 |
0.1% | 0.1% |
0.1% 49k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac | ||||||
| Gambia |
1.3% 31,254 |
0.5% 12,303 |
0.0% | 0.0% |
0.0% 0k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Nigeria |
1.2% 2,534,205 |
0.7% 1,404,740 |
0.0% | 0.0% |
0.1% 106k |
|
| Oxford/AstraZeneca | ||||||
| Guinea-Bissau |
1.2% 24,000 |
0.1% 1,225 |
0.0% | 0.0% |
0.0% 1k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Mozambique |
1.2% 372,085 |
1.0% 318,955 |
0.1% |
0.1% 20k |
||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Cameroon |
1.0% 279,987 |
0.2% 51,888 |
0.1% | 0.0% |
0.1% 18k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Sierra Leone |
1.0% 82,145 |
0.2% 15,170 |
0.8% 60k |
|||
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Somalia |
1.0% 162,655 |
0.6% 87,135 |
0.1% | 0.1% |
0.2% 24k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac | ||||||
| Yemen |
1.0% 298,161 |
0.0% 13,322 |
0.0% | 0.0% |
0.0% 7k |
|
| Oxford/AstraZeneca | ||||||
| Papua New Guinea |
0.9% 78,399 |
0.1% 9,944 |
0.1% | 0.1% |
0.1% 13k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Mali |
0.7% 145,016 |
0.3% 51,846 |
0.0% | 0.0% |
0.0% 7k |
|
| Oxford/AstraZeneca | ||||||
| Madagascar |
0.7% 197,001 |
0.0% |
0.0% 7k |
|||
| Oxford/AstraZeneca | ||||||
| Syria |
0.7% 121,909 |
0.1% 9,312 |
0.0% | 0.0% |
0.1% 9k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V | ||||||
| South Sudan |
0.5% 52,226 |
0.0% 4,763 |
0.1% | 0.0% |
0.0% 1k |
|
| Oxford/AstraZeneca | ||||||
| Eswatini |
0.4% 38,326 |
0.3% 27,341 |
0.0% | 0.1% |
0.1% 6k |
|
| Oxford/AstraZeneca | ||||||
| Benin |
0.4% 43,377 |
0.1% 14,509 |
0.0% | 0.0% |
0.0% 3k |
|
| Oxford/AstraZeneca, Sinovac | ||||||
| Burkina Faso |
0.2% 34,749 |
0.0% 2,371 |
0.0% | 0.0% |
0.0% 2k |
|
| Oxford/AstraZeneca | ||||||
| Chad |
0.1% 22,445 |
0.1% 7,535 |
0.0% | 0.0% |
0.0% 1k |
|
| Sinopharm/Beijing | ||||||
| Democratic Republic of Congo |
0.1% 78,871 |
0.0% 2,513 |
0.0% | 0.0% |
0.0% 4k |
|
| Oxford/AstraZeneca | ||||||
| Haiti |
0.1% 6,576 |
0.0% 341 |
0.0% |
0.0% 4k |
||
| Johnson&Johnson, Oxford/AstraZeneca | ||||||
| PEOPLE VACCINATED | LAST 7 DAYS | |||||
| countries below 1M population |
1st dose |
last dose |
1st dose |
last dose |
any dose |
|
| Gibraltar |
116.7% 39,329 |
116.0% 39,077 |
0.0% | 0.1% |
0.1% 0k |
|
| Pfizer/BioNTech | ||||||
| Malta |
90.5% 399,690 |
86.6% 382,255 |
1.5% | 2.7% |
3.5% 15k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Iceland |
78.9% 269,095 |
74.6% 254,443 |
0.4% | 0.2% |
0.6% 2k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Isle of Man |
76.3% 64,872 |
69.5% 59,075 |
0.4% | 2.0% |
2.4% 2k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Cayman Islands |
76.0% 49,960 |
72.7% 47,747 |
0.7% | 1.1% |
1.8% 1k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Falkland Islands |
75.6% 2,632 |
51.0% 1,775 |
0.8% | 1.7% |
2.4% 0k |
|
| Oxford/AstraZeneca | ||||||
| Seychelles |
74.1% 72,882 |
69.7% 68,553 |
0.6% | 0.2% |
0.8% 1k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Jersey |
73.2% 73,964 |
65.6% 66,281 |
0.8% | 4.0% |
4.8% 5k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Faeroe Islands |
70.9% 34,657 |
59.3% 29,003 |
1.0% | 3.3% |
4.3% 2k |
|
| Moderna, Pfizer/BioNTech | ||||||
| San Marino |
68.3% 23,174 |
68.3% 23,174 |
0.8% | 0.8% |
1.1% 0k |
|
| Pfizer/BioNTech, Sputnik V | ||||||
| Aruba |
68.2% 72,795 |
61.5% 65,718 |
0.6% | 1.5% |
2.2% 2k |
|
| Pfizer/BioNTech | ||||||
| Bermuda |
67.2% 41,873 |
65.8% 40,997 |
0.4% | 0.3% |
0.6% 0k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Greenland |
64.0% 36,324 |
45.3% 25,726 |
3.8% | 9.1% |
12.9% 7k |
|
| Moderna | ||||||
| Turks and Caicos Islands |
63.5% 24,567 |
58.6% 22,696 |
0.5% | 1.8% |
2.4% 1k |
|
| Pfizer/BioNTech | ||||||
| Bhutan |
63.0% 486,242 |
0.3% 2,630 |
0.1% | 0.1% |
0.2% 1k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Luxembourg |
62.7% 392,467 |
49.5% 309,624 |
0.4% | 3.5% |
3.9% 24k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Andorra |
62.7% 48,445 |
43.9% 33,904 |
7.0% | 8.9% |
16.0% 12k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Anguilla |
62.6% 9,398 |
57.3% 8,603 |
0.2% | 1.0% |
1.3% 0k |
|
| Oxford/AstraZeneca | ||||||
| Cyprus |
60.6% 530,879 |
51.3% 449,525 |
1.8% | 1.5% |
3.4% 29k |
|
| Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Maldives |
59.5% 321,523 |
48.5% 262,128 |
0.1% | 0.4% |
0.5% 3k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing | ||||||
| Curacao |
56.5% 92,683 |
50.2% 82,446 |
0.4% | 0.6% |
1.0% 2k |
|
| Moderna, Pfizer/BioNTech | ||||||
| Sint Maarten (Dutch part) |
55.7% 23,885 |
47.0% 20,157 |
0.8% | 1.2% |
2.0% 1k |
|
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Monaco |
55.5% 21,796 |
48.0% 18,834 |
1.7% | 0.5% |
2.1% 1k |
|
| Pfizer/BioNTech | ||||||
| Liechtenstein |
54.1% 20,632 |
49.4% 18,854 |
0.0% | 1.0% |
1.0% 0k |
|
| Moderna, Pfizer/BioNTech | ||||||
| British Virgin Islands |
51.7% 15,620 |
36.0% 10,881 |
5.4% | 2.5% |
7.9% 2k |
|
| Oxford/AstraZeneca | ||||||
| Fiji |
49.2% 441,171 |
10.9% 97,268 |
5.4% | 2.1% |
7.4% 67k |
|
| Oxford/AstraZeneca | ||||||
| Guernsey |
49.2% 32,969 |
20.3% 13,618 |
2.9% 2k |
|||
| Moderna, Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| Saint Kitts and Nevis |
44.9% 23,872 |
37.2% 19,768 |
0.4% | 0.3% |
0.7% 0k |
|
| Oxford/AstraZeneca | ||||||
| Antigua and Barbuda |
39.0% 38,146 |
31.4% 30,704 |
0.6% | 0.4% |
1.0% 1k |
|
| Oxford/AstraZeneca | ||||||
| Barbados |
34.5% 99,278 |
26.0% 74,851 |
0.3% | 0.4% |
0.7% 2k |
|
| Oxford/AstraZeneca | ||||||
| Suriname |
31.9% 187,094 |
10.2% 59,688 |
0.6% | 1.2% |
1.8% 11k |
|
| Oxford/AstraZeneca | ||||||
| Guyana |
31.9% 250,712 |
17.6% 138,624 |
0.8% | 1.2% |
2.0% 16k |
|
| Oxford/AstraZeneca, Sputnik V | ||||||
| Belize |
31.9% 126,693 |
12.3% 49,042 |
2.6% | 1.3% |
3.9% 15k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Brunei |
30.8% 134,829 |
6.7% 29,170 |
2.9% | 1.4% |
4.2% 18k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Samoa |
30.3% 60,044 |
10.6% 21,070 |
2.5% | 2.7% |
5.2% 10k |
|
| Oxford/AstraZeneca | ||||||
| Dominica |
29.0% 20,851 |
27.2% 19,599 |
0.1% | 0.1% |
0.2% 0k |
|
| Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Montserrat |
28.8% 1,439 |
25.8% 1,291 |
0.3% |
0.4% 0k |
||
| Oxford/AstraZeneca | ||||||
| Montenegro |
28.3% 177,757 |
24.6% 154,265 |
1.5% | 0.8% |
2.4% 15k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V | ||||||
| Cape Verde |
25.4% 141,276 |
3.3% 18,170 |
4.2% | 0.5% |
4.8% 26k |
|
| Oxford/AstraZeneca, Pfizer/BioNTech | ||||||
| New Caledonia |
23.2% 66,159 |
20.9% 59,583 |
0.4% | 0.5% |
0.9% 3k |
|
| Pfizer/BioNTech | ||||||
| Bonaire Sint Eustatius and Saba |
21.8% 5,726 |
6.3% 1,665 |
||||
| Moderna, Pfizer/BioNTech | ||||||
| Grenada |
18.7% 21,014 |
13.8% 15,510 |
0.3% | 0.3% |
0.7% 1k |
|
| Oxford/AstraZeneca | ||||||
| Saint Lucia |
17.6% 32,291 |
13.5% 24,775 |
0.2% | 0.5% |
0.6% 1k |
|
| Oxford/AstraZeneca | ||||||
| Bahamas |
15.4% 60,578 |
11.2% 43,943 |
0.0% | 0.6% |
0.6% 3k |
|
| Oxford/AstraZeneca | ||||||
| Sao Tome and Principe |
14.6% 32,090 |
5.4% 11,870 |
1.1% | 0.1% |
1.1% 3k |
|
| Oxford/AstraZeneca | ||||||
| Saint Vincent and the Grenadines |
14.2% 15,726 |
8.9% 9,909 |
0.0% | 0.0% |
0.0% 0k |
|
| Oxford/AstraZeneca | ||||||
| Comoros |
9.7% 84,740 |
4.7% 41,220 |
1.8% |
1.5% 13k |
||
| Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing | ||||||
| Vanuatu |
7.8% 23,881 |
0.0% 114 |
1.5% | 0.0% |
1.5% 5k |
|
| Oxford/AstraZeneca | ||||||
| Solomon Islands |
5.1% 35,167 |
1.5% 9,934 |
2.1% | 0.4% |
2.5% 17k |
|
| Oxford/AstraZeneca | ||||||
| Djibouti |
1.3% 12,547 |
0.9% 8,810 |
0.2% 2k |
|||
| Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V | ||||||